New York, New York (PRWEB) July 14, 2013
As Pradaxa lawsuit claims continue to move forward in courts throughout the U.S., Bernstein Liebhard LLP notes that a new study has reported a link between Pradaxa and an increased of risk of heart attacks. The research, presented July 1st at the 2013 Congress of the International Society on Thrombosis and Haemostasis meeting in Amsterdam, the Netherlands, reported that overall, patients taking Pradaxa had a 32% higher risk of suffering a heart attack compared to control groups. However, among those taking the highest dose of the drug – 150 mg – the risk was elevated by 45%. The findings were based on a meta-analysis of 10 studies involving more than 23,000 patients who had been treated with Pradaxa, other therapies or placebo.*
“We hear from individuals on a regular basis who have allegedly suffered frightening and life-threatening episodes of Pradaxa bleeding. This study just serves as a reminder that Pradaxa can be associated with some very serious side effects,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Pradaxa bleeding.
Pradaxa was approved in October 2010, and was touted as an improvement over warfarin, a blood thinner that has been in use for decades. Court records indicate that more than 1,100 Pradaxa lawsuits are currently pending in a multidistrict litigation currently underway in U.S. District Court, Southern District of Illinois. All of the claims allege that Boehringer Ingelheim failed to adequately warn about the lack of an antidote for Pradaxa bleeding. The first trial in the
Copyright©2012 Vocus, Inc.
All rights reserved